Table 2.
Cancer-related side effects summary
| Variable | Liraglutide dose | Side effect | Other consideration |
|---|---|---|---|
| Cancer | 0.1–1.8 mg | Increase when only methodological studies of high quality were considered.31 | - |
| Thyroid cancer | 0.1–1.8 mg | No increase31 | Cases of medullary thyroid carcinoma have been reported during post-approval use.1 |
| Pancreatic cancer | 1.2 and 1.8 mg | No increase32,41,42 | Pancreatic cancer was more commonly reported among patients with T2DM who took GLP-1 receptor agonists.43 |
| Breast cancer | 1.8 and 3.0 mg | No increase44 | Significant increase in breast cancer risk was identified in patients using GLP-1 receptor agonists for 2–3 years.45 |
| Prostate cancer | - | No reports to date relating liraglutide to an increased risk of prostate cancer | - |
T2DM, type 2 diabetes mellitus; GLP-1, glucagon-like peptide-1.